We are focused on developing differentiated products for the treatment and prevention of serious
infectious diseases. Our clinical-stage programs include FV-100, a potent, orally available, antiviral
for the treatment of herpes zoster (shingles), and Aurexis
®, a humanized monoclonal antibody
for the adjunct treatment of serious
S. aureus infections. Antiviral programs in pre-clinical development
include differentiated oral compounds for the treatment of HCV.
| Antiviral |
|
FV-100 (shingles)
|
 |
| INX-189 (HCV) |
 |
| Antibacterial |
|
| Aurexis (SAB) |
 |
| Staph vaccine |
* |
Footnotes:
* Partnered with
Pfizer